Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Lytix Biopharma to present at the American Society of Clinical Oncology (ASCO) Annual Meeting

OSLO, Norway, April 28, 2022 /PRNewswire/ -- Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022.

Title: LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.
Presenter: Morten Nielsen, MD | National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Poster Session: Sarcoma
Abstract: 11567
Poster: 471

For further information please contact:
Øystein Rekdal (CEO)
Telephone: +47 975 73 358
E-mail: Oystein.Rekdal@lytixbiopharma.com

Ole Peter Norby (Head of Investor Relations)
Phone: +47 412 87 179
Email: ole.peter.nordby@lytixbiopharma.com

About Lytix Biopharma AS

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient's immune system to fight cancer. The Company's technology is based on pioneering research in "host defense peptides" ? nature's first line of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient's tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a U.S. based, healthcare-focused investment firm. For more information, visit www.lytixbiopharma.com.

About LTX-315

LTX-315 is a potential first-in-class oncolytic molecule administered directly into a tumor to induce immunogenic cell death. The technology is based on pioneering research in "host defense peptides" ? nature's first line of defense towards foreign pathogens. LTX-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.

About in situ vaccination

In situ vaccination stimulates a patient's immune system by injecting drugs with the ability to kill cancer cells straight into the tumor environment. Lytix Biopharma has applied this approach with its first-in-class oncolytic molecules, representing an alternative and unique approach to cancer vaccination. Importantly, this approach generates an immune response against a broad antigen repertoire without pre-identifying the antigens, which in turn can save considerable costs and valuable time.

This information was brought to you by Cision http://news.cision.com



SOURCE Lytix Biopharma AS

These press releases may also interest you

at 09:00
Ziegler, a specialty investment bank, is pleased to announce the successful closing of a $17,775,000 taxable bank placement for The View Alexandria by Goodwin Livingtm, a subsidiary of Goodwin Living...

13 aoû 2022
At least 5% of Americans suffer from chronic low back pain. [1] Over $630 billion is spent annually on costs to society [2], and chiropractic care is essential in managed post-surgical spinal pain [3] and scoliosis [4]. To prepare clinicians...

13 aoû 2022
Ziegler is pleased to announce the successful closing of Shenandoah Valley Westminster-Canterbury's $71,000,000 Series 2022A and 2022B Bonds for the Senior Living Finance Practice. Shenandoah Valley Westminster-Canterbury (SVWC) is a Virginia...

12 aoû 2022
The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of LifeStance Health Group, Inc. common stock issued in connection with LifeStance Health's June 10, 2021 initial...

12 aoû 2022
An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and...

12 aoû 2022
Core One Labs Inc. , , (the "Company" or "Core One") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. ("Awakened") have successfully produced a precursor that can be...

News published on 28 april 2022 at 06:53 and distributed by: